首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Bone marrow of multiorgan donors underutilized: implications for improvement of accessibility of hematopoietic cells for transplantations.
【24h】

Bone marrow of multiorgan donors underutilized: implications for improvement of accessibility of hematopoietic cells for transplantations.

机译:多器官供体的骨髓利用不足:对改善造血细胞可移植性的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The demand for human hematopoietic stem and progenitor cells (HSPCs) for transplantation is increasing. Thus, effective alternative sources of HSPCs are required. Consequently, we sought to expand the accessibility of hematopoietic cells for clinical purposes by the investigation of hematopoietic reconstitution after transplantation of human HSPCs harvested from the bone marrow (BM) of heparinized deceased organ donors (HDODs). METHODS: For multipart research comparison, human BM HDODs-, healthy donor-derived, umbilical cord blood nuclear cells, or CD34(+) cells were transplanted into sublethally irradiated NOD/SCID mice. Twenty-eight days after transplantation nuclear cells were isolated from the murine BM, spleen, and peripheral blood and were used to quantitatively detect human CD45 antigen by quantitative real-time reverse transcriptase-polymerase chain reaction and flow cytometry. The clonogenic growth of human colony-forming units was also investigated. RESULTS: We found that umbilical cord blood-derived HSPCs showed the greatest transplantation potential in our in vivo model. Interestingly, the transplantation potential of HSPCs collected from the BM of HDODs was of the same quality as cells obtained from healthy BM donors. CONCLUSION: Based on these results, we conclude that HDODs are a strongly underappreciated source of HSPCs that are ready to use for clinical purposes.
机译:背景:用于移植的人类造血干细胞和祖细胞(HSPC)的需求正在增加。因此,需要有效的HSPC替代来源。因此,我们试图通过研究从肝素化已故器官供体(HDODs)的骨髓(BM)收获的人HSPC移植后造血重建的研究,扩大用于临床目的的造血细胞的可及性。方法:为了进行多部分研究比较,将人BM HDODs,健康供体来源的脐带血核细胞或CD34(+)细胞移植到经亚致死剂量照射的NOD / SCID小鼠中。移植后第二十八天,从鼠的BM,脾脏和外周血中分离出核细胞,并通过定量实时逆转录酶-聚合酶链反应和流式细胞术定量检测人CD45抗原。还研究了人类菌落形成单位的克隆生长。结果:我们发现脐血来源的HSPCs在我们的体内模型中显示出最大的移植潜力。有趣的是,从HDODs的BM收集的HSPC的移植潜力与从健康的BM供体获得的细胞具有相同的质量。结论:基于这些结果,我们得出结论,HDODs是可用于临床目的的HSPC的一种被严重低估的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号